Bone Biologics
Biotechnology, 2 Burlington Woods Dr, Los Angeles, California, 01803, United States, 11-50 Employees
Phone Number: +19*********
Who is BONE BIOLOGICS
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and f...
Read More
-
Headquarters: 2 Burlington Woods Dr, Los Angeles, California, 01803, United States
-
Date Founded: 2004
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Jeff Frelick
Email
Phone
Industry: Biotechnology
SIC Code: 3826
|
NAICS Code: 541711 |
Show More
Does something look wrong? Fix it. | View contact records from BONE BIOLOGICS
Bone Biologics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Bone Biologics
Answer: Bone Biologics's headquarters are located at 2 Burlington Woods Dr, Los Angeles, California, 01803, United States
Answer: Bone Biologics's phone number is +19*********
Answer: Bone Biologics's official website is https://bonebiologics.com
Answer: Bone Biologics's revenue is $1 Million to $5 Million
Answer: Bone Biologics's SIC: 3826
Answer: Bone Biologics's NAICS: 541711
Answer: Bone Biologics has 11-50 employees
Answer: Bone Biologics is in Biotechnology
Answer: Bone Biologics contact info: Phone number: +19********* Website: https://bonebiologics.com
Answer: A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka University professor and a USC surgeon and acquired in 2006 by MTF as the major shareholder, who has been the primary funder since the acquisition. The Companys proprietary, patented platform technology UCB-1TM, exclusively licensed from UCLA, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and Rhesus Monkey) studies that have demonstrated that the UCB-1TM technology facilitates superior normal bone growth. The company believes that as a platform technology, UCB-1TM has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration. Bone Biologics lead product is focused on bone regeneration in human lumbar spinal fusion using our recombinant human protein growth factor, known as Nell-1. Nell-1 is currently under development and progressing toward near term clinical trial studies in human lumbar fusion because Bone Biologics believes that lumbar surgeons are currently underserved by suitable quality outcome results and are receptive to new biological therapies that are target specific. Our mission is to utilize the power of Nell-1 to improve clinical outcomes and reduce total health care delivery costs associated with lumbar spinal fusion. The company is focused on bone repair and regeneration applications and is committed to exploring additional applications of the UCB-1TM technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month